Kt Corporation ADR Stock
Price
Target price
€15.30
€15.30
-0.650%
-0.1
-0.650%
-
17.07.26 / Stuttgart Stock Exchange
WKN: 922613 / Symbol: KTC / Name: KT / Stock / Telecommunications Services / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Kt Corporation ADR Stock
The price for the Kt Corporation ADR stock decreased slightly today. Compared to yesterday there is a change of -€0.100 (-0.650%).
Pros and Cons of Kt Corporation ADR in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
B****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Kt Corporation ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Kt Corporation ADR | -0.650% | -2.548% | -3.774% | -14.045% | -3.165% | 48.544% | 26.446% |
| Freenet AG | 0.920% | 1.597% | -3.435% | -12.455% | -18.034% | 6.520% | 21.875% |
| Elisa Oyj A | 0.170% | -2.759% | -7.263% | -23.986% | -6.277% | -28.403% | -35.268% |
| Telekom Austria AG | 1.100% | 0.399% | 4.033% | 4.683% | 12.027% | 48.159% | 37.620% |
News
Kymera's CEO Sold $6 Million in Stock After a 170% Run
Chief Executive Officer Nello Mainolfi sold 50,000 shares of Kymera Therapeutics (NASDAQ:KYMR) on July 7, 2026, for total proceeds of about $6.0 million, according to an SEC Form 4 filing.
Kymera
Why Kymera Therapeutics Stock Popped This Week
This week was an eventful one for Kymera Therapeutics (NASDAQ: KYMR). The clinical-stage biotech announced the early completion of enrollment in an important clinical trial. It also earned a clutch
Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data
Key Points
- Interested in Kymera Therapeutics, Inc.? Here are five stocks we like better.
- Kymera said its lead program KT-621 remains on schedule in Phase IIb trials for atopic dermatitis and
